advertisement
Abstract #77167 Published in IGR 19-3
Pretarsal skin height changes in children receiving topical prostaglandin analogue therapy for primary congenital glaucoma
Al-Zobidi M; Khandekar R; Cruz A; Craven RE; Souru C; Malik R; Edward DPJournal of AAPOS 2018; 22: 290-293.e1
PURPOSE: To compare pretarsal skin height (PTSH), as proxy indicator of deepening of the upper eyelid sulcus, in children with primary congenital glaucoma (PCG) treated with topical prostaglandin analogues (PGAs) with PTSH in healthy children (control group 1) and children with PCG but not using PGAs (control group 2). METHODS: We recruited children with PCG who had been using PGAs for at least 6 months (PCG/PGA group). PTSH in all participants was measured using ImageJ software from photographs taken in a standardized manner. The PTSH was compared for the PCG group and both control groups. RESULTS: A total of 34 children with PCG and 41 controls (31 in group 1; 10 in group 2) were included. The difference in PTSH between children in the PCG/PGA group and both control groups was statistically significant (mean difference, ≥1.7 mm [P < 0.01]). CONCLUSIONS: The PTSH was significantly greater in children with PCG using PGAs compared to children with PCG not using PGAs and healthy children. Children and their parents should be counseled about lid abnormalities prior to commencing treatment with PGAs.
King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
Full articleClassification:
9.1.1 Congenital glaucoma, Buphthalmos (Part of: 9 Clinical forms of glaucomas > 9.1 Developmental glaucomas)
11.4 Prostaglandins (Part of: 11 Medical treatment)
